company background image
PHVS

Pharvaris NasdaqGS:PHVS Stock Report

Last Price

US$5.55

Market Cap

US$187.4m

7D

-29.1%

1Y

-68.7%

Updated

04 Oct, 2022

Data

Company Financials +
PHVS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PHVS Stock Overview

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.

Pharvaris N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharvaris
Historical stock prices
Current Share PriceUS$5.55
52 Week HighUS$27.50
52 Week LowUS$5.38
Beta0
1 Month Change-40.96%
3 Month Change-76.67%
1 Year Change-68.70%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.86%

Recent News & Updates

Sep 26
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Sep 12

Pharvaris GAAP EPS of -€0.38

Pharvaris press release (NASDAQ:PHVS): Q2 GAAP EPS of -€0.38. Cash and cash equivalents were €201 million as of June 30, 2022, compared to €209 million as of December 31, 2021.

Aug 22

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Pharvaris N.V. (NASDAQ:PHVS) dropped ~19% in the pre-market trading Monday after the Dutch biopharma announced that the FDA verbally notified its plans to issue a clinical hold on the clinical trials of hereditary angioedema candidate PHA121. The decision is based on a review of nonclinical data, and the agency intends to offer a formal clinical hold letter within the next 30 days. A small molecule bradykinin B2-receptor antagonist, PHA121, was undergoing clinical studies in the U.S. under two Investigational New Drug (IND) applications for HAE. “We are fully committed to working closely with the FDA to address the agency’s concerns,” PHVS Chief Executive Berndt Modig remarked.

Shareholder Returns

PHVSUS PharmaceuticalsUS Market
7D-29.1%2.6%4.4%
1Y-68.7%5.8%-18.2%

Return vs Industry: PHVS underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: PHVS underperformed the US Market which returned -20% over the past year.

Price Volatility

Is PHVS's price volatile compared to industry and market?
PHVS volatility
PHVS Average Weekly Movement14.3%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: PHVS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PHVS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201547Berndt Axel Modighttps://pharvaris.com

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial.

Pharvaris N.V. Fundamentals Summary

How do Pharvaris's earnings and revenue compare to its market cap?
PHVS fundamental statistics
Market CapUS$187.40m
Earnings (TTM)-US$49.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHVS income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€50.13m
Earnings-€50.13m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.48
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PHVS perform over the long term?

See historical performance and comparison